Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update
Agency IQ
FEBRUARY 2, 2024
The revisions flesh out considerations for use of biomarkers at all stages of product development and add new content on rare cancers and platform trial designs. after ischemic heart disease and stroke. See AgencyIQs analysis of a workshop on novel methodology qualification.] were from cancer.
40 
Let's personalize your content